In the BioHarmony Drug Report Database

"Preview" Icon

Volanesorsen

Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.

 

Trade Name

 

Waylivra
 

Common Name

 

volanesorsen
 

ChEMBL ID

 

CHEMBL3544994
 

Indication

 

hyperlipoproteinemia type i
 

Drug Class

 

Antisense oligonucleotides

Image (chem structure or protein)

Volanesorsen structure rendering